Cambridge Investment Research Advisors, Inc. Exelixis, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 84,092 shares of EXEL stock, worth $3.73 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
84,092
Previous 68,909
22.03%
Holding current value
$3.73 Million
Previous $2.3 Million
35.29%
% of portfolio
0.01%
Previous 0.01%
Shares
33 transactions
Others Institutions Holding EXEL
# of Institutions
642Shares Held
257MCall Options Held
1.67MPut Options Held
733K-
Black Rock Inc. New York, NY33.5MShares$1.49 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.27 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$1 Billion4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$658 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$523 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $14.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...